Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649993 | 0.90 | LMNA (0.43) | LMNAPOLBMAPTTRPV4THRB | |
| SCHEMBL6643832 | 0.89 | NAMPT (0.42) | LMNAPOLBMAPTTHRBHIF1A | |
| SCHEMBL7201167 | 0.88 | THRB (0.40) | LMNAMAPTTHRBHIF1APTGDR2 | |
| SCHEMBL6650061 | 0.87 | SMN1; SMN2 (0.42) | MAPTTHRBHIF1A | |
| SCHEMBL6687617 | 0.87 | LMNA (0.51) | LMNAPOLBMAPTTHRBHIF1A | |
| SCHEMBL6647472 | 0.85 | THRB (0.43) | LMNAMAPTTHRBHIF1A | |
| SCHEMBL6645504 | 0.84 | TRPV4 (0.42) | MAPTTRPV4HIF1A | |
| SCHEMBL6642961 | 0.79 | THRB (0.38) | LMNAPOLBMAPTTRPV4THRB | |
| SCHEMBL6644597 | 0.78 | F2 (0.39) | POLBMAPTTHRBHIF1AGPR27 | |
| SCHEMBL6646119 | 0.77 | THRB (0.40) | LMNAPOLBTHRBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | LMNA 1410/4885POLB 1209/4885MAPT 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.